1
Clinical Trials associated with Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine(BioNet-Asia)A phase III randomized, observer-blind, active-controlled study to compare the safety and immunogenicity of an investigational combined Tetanus-diphtheria-recombinant acellular pertussis vaccine (BioNet Tdap) and licensed recombinant TdaP vaccine (Boostagen), investigational recombinant monovalent acellular pertussis vaccine (BioNet ap) and licensed recombinant aP vaccine (Pertagen), and another licensed Tdap vaccine, when administered to healthy adults aged of 18-75 years old
100 Clinical Results associated with Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine(BioNet-Asia)
100 Translational Medicine associated with Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine(BioNet-Asia)
100 Patents (Medical) associated with Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine(BioNet-Asia)
100 Deals associated with Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine(BioNet-Asia)